Cost-effectiveness analysis of universal childhood vaccination against varicella in Brazil

Vaccine

Volumn 26, Issue 49, 2008, Pages 6281-6291

  Valentim, J ^a   Sartori, A M C ^a   de Soarez P C ^a   Amaku, M ^a   Azevedo, R S ^a   Novaes, H M D ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Brazil; Cost effectiveness; Varicella vaccine

Indexed keywords

CHICKENPOX VACCINE;

ARTICLE; BRAZIL; CHICKENPOX; CHILD; CHILDHOOD DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; INCIDENCE; INFECTION PREVENTION; PRIORITY JOURNAL; SINGLE DRUG DOSE;

EID: 55549094063     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.07.021     Document Type: Article

References (68)

1. Hambleton S., and Gershon A.A. Preventing varicella-zoster disease. Clin Microbiol Rev 18 1 (2005) 70-80
2. Heininger U., and Seward J.F. Varicella. Lancet 368 (2006) 1365-1376
3. Seward J.F., Marin M., and Vázquez M. Varicella effectiveness in the US vaccination program: a review. J Infect Dis 197 Suppl. 2 (2008) S82-S89
4. Galea S.A., Sweet A., Beninger P., Steinberg S.P., LaRussa P.S., Gershon A.A., et al. The safety profile of varicella vaccine: a 10-year review. J Infect Dis 197 Suppl. 2 (2008) S165-S169
5. Hambleton S., Phill D., and Gershon A.A. The impact of varicella vaccination in the United States. Semin Pediatr Infect Dis 16 (2005) 38-43
6. Nguyen H.Q., Jumaan A.O., and Seward J.F. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med 352 (2005) 450-458
7. Zhou F., Harpaz R., Jumaan A.O., Winston C.A., and Shefer A. Impact of varicella vaccination on health care utilization. JAMA 294 7 (2005) 797-802
8. Guris D., Jumaan A.O., Mascola L., Watson B.M., Zhang J.X., Chaves S.S., et al. Changing varicella epidemiology in active surveillance-United States. 1995-2005. J Infect Dis 197 Suppl. 2 (2008) S71-S75
9. Marin M., Watson T.L., Chaves S.S., Civen R., Watson B.M., Zhang J.X., et al. Varicella among adults: data from an active surveillance project, 1995-2005. J Infect Dis 197 Suppl. 2 (2008) S94-100
10. Ministério da Saúde, Brasil. Programa Nacional de Imunizações (PNI). Imunobiológicos Especiais e suas Indicações. Available from: . Accessed January 28, 2008.
11. Wagenpfeil S., Neiss A., and Wutzler P. Effects of varicella vaccination on herpes zoster incidence. Clin Microbiol Infect 10 (2004) 954-960
12. Thiry N., Beutels P., Van Damme P., and Van Doorslaer E. Economic evaluations of varicella vaccination programmes. A review of the literature. Pharmacoeconomics 21 1 (2003) 13-38
13. Yu A.L.F., Costa J.M., Amaku M., Pannuti C.S., Souza V.A., Zanetta D.M., et al. Three year seroepidemiological study of varicella-zoster virus in São Paulo, Brazil. Rev Inst Med Trop, S Paulo 42 3 (2000) 125-128
14. Yu A.L.F., Amaku M., Burattini M.N., Massad E., and Azevedo R.S. Varicella transmission in two samples of children with different social behaviour in the State of São Paulo, Brazil. Epidemiol Infect 127 (2001) 493-500
15. WHO (World Health Organization). Making choices in health: WHO guide to cost-effectiveness analysis (2003), WHO, Geneva
16. Lieu T.A., Cochi S.L., Black S.B., Halloran M.E., Shinefield H.R., Holmes S.J., et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA 271 5 (1994) 375-381
17. Huse D.M., Meissner H.C., Lacey M.J., and Oster G. Childhood vaccination against chickenpox: an analysis of benefits and costs. J Pediatr 124 6 (1994) 869-874
18. Beutels P., Clara R., Tormans G., et al. Costs and benefits of routine varicella vaccination in German children. J Infect Dis 174 Suppl. 3 (1996) S335-S341
19. Coudeville L., Paree F., Lebrun T., et al. The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France. Vaccine 17 2 (1999) 142-151
20. Scuffham P., Devlin N., Eberhart-Phillips J., and Wilson-Salt R. The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunization schedule. Soc Sci Med 49 6 (1999) 763-779
21. Díez Domingo J., Ridao M., Latour J., et al. A cost benefit analysis of routine varicella vaccination in Spain. Vaccine 17 11-12 (1999) 1306-1311
22. Scuffham P.A., Lowin A.V., and Burgess M.A. The cost-effectiveness of varicella vaccine programs for Australia. Vaccine 18 5-6 (2000) 407-415
23. Hsu H.C., Lin R.S., Tung T.H., and Chen T.H.H. Cost-benefit analysis of routine childhood vaccination against chickenpox in Taiwan: decision from different perspectives. Vaccine 21 (2003) 3982-3987
24. Hanslik T., Boelle P.Y., Schwarzinger M., et al. Varicella in French adolescents and adults: individual risk assessment and cost-effectiveness of routine vaccination. Vaccine 21 (2003) 3614-3622
25. Banz K., Wagenpfeil S., Neiss A., Goertz A., Staginnus U., Vollmar J., et al. The cost-effectiveness of routine childhood varicella vaccination in Germany. Vaccine 21 (2003) 1256-1267
26. Pena-Rey I., Pérez-Farinós N., Cortés-García M., and Amela-Heras C. Coste-efectividad de la vacunación contra la varicela en adolescents en Espana. Gac Sanit 18 4 (2004) 287-294
27. Coudeville L., Brunot A., Giaquinto C., Lucioni C., and Dervaux B. Varicella vaccination in Italy: an economic model evaluation of different scenarios. Pharmacoeconomics 22 13 (2004) 839-855
28. Ginsberg G., and Somekh M.E. Cost containment analysis of childhood vaccination against varicella in Israel. J Infect 48 (2004) 119-133
29. Coudeville L., Brunot A., Szucs T.D., and Dervaux B. The economic value of childhood varricella vaccination in France and Germany. Value Health 8 3 (2005) 209-222
30. Lenne X., Diez Domingo J., Gil A., Ridao M., Lluch J.A., and Dervaux B. Economic evaluation of varicella vaccination in Spain-results from a dynamic model. Vaccine 24 (2006) 6980-6989
31. Zhou F., Ortega-Sanchez, Guris D., Shefer A., Lieu T., and Seward J.F. An economic analysis of the universal varicella vaccination program in the United States. J Infect Dis 197 Suppl. 2 (2008) S156-S164
32. Reynolds M.A., Chaves S.S., Harpaz R., Lopez A.S., and Seward J.F. The impact of the varicella vaccination program on herpes zoster epidemiology in the United States: a review. J Infect Dis 197 Suppl. 2 (2008) S224-S227
33. Ministério da Saúde. DATASUS. Sistema de Informação Hospitalar (SIH/DATASUS). Cd-rom 2003, 2004.
34. IBGE (Instituto Brasileiro de Geografia e Estatística). Pesquisa Nacional de Amostra de Domicílios (PNAD) 2003. Cd-rom, 2003.
35. Ministério da Saúde. DATASUS. Sistema de Informações sobre Mortalidade (SIM/DATASUS). Available from: . Accessed June 15, 2006.
36. IBGE (Instituto Brasileiro de Geografia e Estatística). Censo Demográfico 2000. Available from: . Acessed: September 15, 2006.
37. Whitley R.J. Varicella zoster virus. In: Mandell G.L., Bennett J.E., and Dolin R. (Eds). Mandell, Douglas and Bennett's principles and practice of infectious diseases. 6th ed. (2005), Elsevier Churchill Livingstone 1780-1786 Chapter 133
38. Brisson M., and Edmunds W.T. The cost-effectiveness of varicella vaccination in Canada. Vaccine 20 (2002) 1113-1125
39. Brisson M., and Edmunds W.J. Varicella vaccination in England and Wales: cost-utility analysis. Arch Dis Child 88 (2003) 862-869
40. Chaves S.S., Zhang J., Civen R., Watson B.M., Carbajal T., Perella D., et al. Varicella disease among vaccinated persons: clinical and epidemiological characteristics 1997-2005. J Infect Dis 197 Suppl. 2 (2008) S127-S131
41. Marin M., Güris D., Chaves S.S., Schmid S., and Seward J.F. Prevention of Varicella Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 56 RR-4 (2007) 1-40
42. Podewils L.J., Antil L., Hummelman E., Bresee J., Parashar U.D., and Rheingans R. Projected cost-effectiveness of rotavírus vaccination for children in Asia. J Infect Dis 192 Suppl. 1 (2005) S133-S145
43. IBGE (Instituto Brasileiro de Geografia e Estatística). Índice Nacional de Preços ao Consumidor Amplo - IPCA e Índice Nacional de Preços ao Consumidor - INPC. Available from: http://www.sidra.ibge.gov.br/bda/precos/default.asp. Accessed: November 15, 2006.
44. FGV (Fundação Getúlio Vargas). Divisão de Gestão de Dados, Índices Gerais de Preços. Available from: http://www2.fgv.br/dgd/asp/dsp_IGP.asp. Accessed: November 15, 2006.
45. Ministério da Saúde. DATASUS. Sistema de Informações Ambulatoriais (SIA/DATASUS). Available from: http://tabnet.datasus.gov.br/cgi/deftohtm.exe?sia/cnv/pauf.def. Accessed: September 15, 2006.
46. NTU (Associação Nacional das Empresas de Transportes Urbanos). Políticas Tarifárias. Available from: http://www.ntu.org.br/banco/tarifas/evoluc_tarifas.htm. Accessed: September 15, 2006.
47. Marcitelli R., and Bricks L. Varicella zoster in children attending day care centers. Clinics 61 2 (2006) 147-152
48. IBGE (Instituto Brasileiro de Geografia e Estatística). Pesquisa Nacional de Amostra de Domicílios (PNAD) 2004. Available from: http://www.sidra.ibge.gov.br/pnad/default.asp. Accessed: September 15, 2006.
49. Walker D., and Fox-Rushby J.A. Allowing for uncertainty in economic evaluations: qualitative sensitivity analysis. Health Policy Plan 16 4 (2001) 435-443
50. WHO (World Health, Organization). The world report 2002-reducing risks, promoting healthy life (2002), WHO, Geneva p. 108
51. IBGE (Instituto Brasileiro de Geografia e Estatística). Sistema de Contas Nacionais. Available from: http://www.ibge.gov.br/home/estatistica/economia/contasnacionais/referen cia2000/2005/default.shtm. Accessed: November 7, 2007.
52. Brisson M., Edmunds W.J., Gay N.J., et al. Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiol Infect 125 (2000) 651-669
53. Goldman G.S. Cost-benefit analysis of universal varicella vaccination in the U S. taking into account the closely related herpes-zoster epidemiology. Vaccine 23 25 (2005) 3349-3355
54. Hammerschmidt T., Bisanz H., and Wutzler P. Universal mass vaccination against varicella in Germany using an MMR combination vaccine with a two-dose schedule: an economic analysis. Vaccine 25 (2007) 7307-7312
55. Kuter B., Matthews H., Shinefield H., Black S., Dennehy P., Watson B., et al. Ten years follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J 23 (2004) 132-137
56. Michalik D.E., Steinberg S.P., LaRussa P.S., Edwards K.M., Wright P.F., Arvin A.M., et al. Primary vaccine failure after 1 dose of varicella vaccine in healthy children. J Infect Dis 197 (2008) 944-949
57. Chaves S.S., Gargiullo P., Zhang J.X., Civen R., Guris D., Mascola L., et al. Loss of vaccine-induced immunity to varicella over time. New Engl J Med 356 (2007) 1121-1129
58. Bayer O., Heininger U., Heiligensentzer C., and von Kries R. Metaanalysis of vaccine effectiveness in varicella outbreaks. Vaccine 25 (2007) 6655-6660
59. Patrick D. Prevention strategies: experience of varicella vaccination programmes. Herpes 14 Suppl. 2 (2007) 48A-51A
60. Sadzot-Delvaux C., Rentier B., Wutzler P., Asano Y., Suga S., Yoshikawa T., et al. Varicella vaccination in Japan South Korea and Europe. J Infect Dis 197 Suppl. 2 (2008) S185-S190
61. Macartney K.K., and Burgess M.A. Varicella vaccination in Austrália and New Zealand. J Infect Dis 197 Suppl. 2 (2008) S191-S195
62. Ministério de Salud Publica, Republica Oriental del Uruguay. Certificado Esquema de Vacunacion Año 2008. Available on line: http://www.msp.gub.uy/noticia_1710_1.html. Accessed in March 29, 2008.
63. Ministério da Saúde. DATASUS. Informações de Saúde. Imunizações - Cobertura. Available from: http://tabnet.datasus.gov.br/cgi/deftohtm.exe?pni/cnv/epniuf.def. Accessed in March 01, 2008.
64. Shinefield H.R., Black S., and Kuter B.J. Varicella immunogenicity with 1- and 2-dose regimens of Measles-Mumps-Rubella-Varicella Vaccine. J Infect Dis 197 Suppl. 2 (2008) S152-S155
65. Amaku M., Coutinho F.A., Azevedo Neto R.S., Burattini M.N., Lopez L.F., and Massad E. Vaccination against rubella: Analysis of the temporal evolution of the age-dependent force of infection and the effects of different contact patterns. Phys Rev E 67 5 Pt. 1 (2003) 051907
66. Costa JM. Estudo Soroepidemiológico da infecção pelo vírus varicela-zoster em duas comunidades da grande São Paulo. Dissertação de Mestrado. Faculdade de Medicina da Universidade de São Paulo, 1995.
67. Azevedo Neto R.S., Silveira A.S., Nokes D.J., Yang H.M., Passos S.D., Cardoso M.R., et al. Rubella seroepidemiology in a non-immunized population of Sao Paulo State, Brazil. Epidemiol Infect 113 (1994) 161-173
68. Griffiths D.A. A catalytic model of infection for measles. Appl Stat 23 (1974) 330-339